Cellular technology breakthrough
for clear vision of the future.


Cellular technology breakthrough
for clear vision of the future.

Corneal transplantation is one of the earliest transplantation therapies used to treat patients and has a history of over a 100 years. There have been remarkable progress in surgical techniques, however, the method still relies heavily on the number of available donors.
Currently, we are facing a global shortage of donor corneas for transplantation. In fact, 12,700,000 patients are waiting for transplants at this moment. However, only 180,000 can receive surgery every year. In other words, only one of seventy-two patients have access to treatment. Among them, the number of bullous keratopathy patients is on the rise with the increase in number of ocular surgeries for age related cataract, glaucoma, etc. In addition, there are many areas in the world that are not covered by an eye bank system. Establishing new eye banks will require time as well as enormous funds. An alternative solution is in dire need.
The mission of Cellusion Inc. is to deliver novel therapies for all bullous keratopathy patients. To do so, we have developed a novel mass culture system for corneal endothelial cells produced from induced pluripotent stem cells (iPS cells). Our technology will allow the medical community to safely treat patients with minimally invasive cell therapy, and solve not only the donor shortage issue, but also reduce surgery time and the risk of complications. We are on the brink of making a major breakthrough for the first time in over 100 years of corneal transplant history.


iPS-derived corneal endothelial cellular therapy will provide a solution
for long-standing corneal transplantation problems.

Current treatment
Penetrating keratoplasty
The host cornea is replaced with donor tissue and manually sutured.
Descemet’s stripping automated endothelial keratoplasty
After removal of the host's pathological endothelium together with basement membrane (Descemet membrane), the donor tissue is inserted into eye and attached by air pressure.
The shortage of corneal donor issue
The risks associated with surgery include astigmatism, glaucoma, immunological rejection and infection, etc.
Requires long surgical time and advanced surgical techniques
Cell transplantation
Injecting corneal endothelial cells manufactured from iPS cells.
Bulk production of iPS-derived corneal cells
Minimum invasive surgery
Only requires simple cell injection by syringe, and then maintaining a face-down position for three hours after treatment.


The pipeline of Cellusion internal programs is below.

Code No. Indication Discovery Preclinical Clinical Approval
PhaseⅠ PhaseⅡ PhaseⅢ
CL S001 Bullous
CL S003 Corneal stromal


Company Name
Cellusion Inc.
#305,1-13-7 Nihombashi-Muromachi, Chuo,
Tokyo 103-0022, JAPAN
January 2015
Capital Stock
640,000 K JPY
Management Team
  • Chief Executive Officer
    Shin Hatou
  • Executive Director
    Tomokatsu Hongo
  • Executive Director
    Joji Hayashida
  • Executive Director
    Toru J. Seo
  • Executive Director
    ChiaoFang (Joyce) Cheng
  • Executive Director
    Naonori Kurokawa
  • Auditor
    Hiroshi Ishiai
  • Auditor
    Hiroaki Kobayashi
  • Auditor
    Ikuo Mashimo
Main Business
R&D, manufacturing, and sales of induced pluripotent stem cell-derived corneal endothelial cells for bullous keratopathy therapy.


We are happy to answer any questions you may have about Cellusion Inc. Fill out this form and someone from our team will be in touch as soon as possible. We will use any personal information provided on this website only to reply to your message.
E-mail address


Copyright CELLUSION All Rights Reserved.